+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort



Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort



Pediatric Transplantation 11(1): 58-65



PTLD is an important complication following heart transplantation. To better define the risk factors of PTLD in children, we performed a case-control study. All pediatric cardiac transplant recipients who developed their first episode of PTLD were matched by age (+/-1 yr) and time since transplant (+/-1 yr) with those who did not. PTLD occurred in nine of 95 cardiac transplant recipients (9%), 0.3-7.8 yr following cardiac transplantation (median = 2.5 yr). Patients were 0.1-16.4 yr (median = 3.7) at transplantation. Biopsies revealed polymorphic B cell hyperplasia (three), polymorphic B cell lymphoma (one), monomorphic diffuse large cell B cell lymphoma (three) and monomorphic Burkitt's-like lymphoma (two). Patients who developed PTLD were at no greater risk of death (p = 0.31). Recipient EBV seronegativity at time of transplant (p = 0.08), EBV seroconversion (p = 0.013) and recipient CMV seronegativity (p = 0.015) were associated with the development of PTLD by conditional logistic regression; sex, race, donor age, recipient diagnosis, donor CMV seropositivity, recipient treatment for CMV infection, EBV seropositivity at the time of PTLD diagnosis, and number of rejection episodes, treated rejection episodes, and lympholytics used were not. There was no significant association between PTLD and death in our recipients. EBV seroconversion and recipient CMV seronegativity were associated with the development of PTLD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048462314

Download citation: RISBibTeXText

PMID: 17239124

DOI: 10.1111/j.1399-3046.2006.00609.x


Related references

Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Transplant Infectious Disease 20(1):, 2018

Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatric Transplantation 9(4): 450-455, 2005

Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leukemia & Lymphoma 36(1-2): 109-121, 1999

Analysis of risk factors for post-transplant lymphoproliferative disease in pediatric lung transplant recipients with cystic fibrosis. Pediatric Research 43(4 Part 2): 131A, 1998

Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort. Leukemia and Lymphoma 46(4): 533-539, 2005

The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Hepatology 36(4 Part 2): 662A, 2002

BK virus nephropathy in a pediatric heart transplant recipient with post-transplant lymphoproliferative disorder: a case report and review of literature. Pediatric Transplantation 17(2): E55-E61, 2013

Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: A multicenter analysis. Clinical Transplantation 33(5): E13521, 2019

Anti-CD20 monoclonal antibody for the treatment of post-transplant lymphoproliferative disease in a pediatric heart transplant recipient. Journal of Investigative Medicine 47(2): 125A, 1999

Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: A multicenter prospective cohort study. Pediatric Transplantation 21(6):, 2017

Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica 89(3): 366-368, 2004

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatric Transplantation 5(5): 359-364, 2001

Risk factors that influence survival in kidney transplant recipients with post-transplant lymphoproliferative disease A multivariate analysis. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 178A, 2002

Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. Journal of Heart and Lung Transplantation 34(11): 1406-1414, 2015

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transplant International 7(Suppl. 1): S235-S237, 1994